Investors purchased shares of McKesson Co. (NYSE:MCK) on weakness during trading on Thursday. $49.21 million flowed into the stock on the tick-up and $30.54 million flowed out of the stock on the tick-down, for a money net flow of $18.67 million into the stock. Of all companies tracked, McKesson had the 32nd highest net in-flow for the day. McKesson traded down ($0.74) for the day and closed at $121.81
Several equities analysts have commented on MCK shares. Jefferies Financial Group reissued a “buy” rating and set a $160.00 target price on shares of McKesson in a research report on Friday, July 27th. Barclays dropped their target price on shares of McKesson from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Friday, October 26th. Royal Bank of Canada set a $155.00 price target on shares of McKesson and gave the stock a “hold” rating in a research note on Friday, October 26th. Mizuho restated a “hold” rating and set a $133.00 price target on shares of McKesson in a research note on Sunday, August 12th. Finally, JPMorgan Chase & Co. decreased their price target on shares of McKesson from $181.00 to $160.00 and set an “overweight” rating for the company in a research note on Friday, July 27th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $150.26.
The company has a current ratio of 0.99, a quick ratio of 0.56 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $23.80 billion, a PE ratio of 9.09, a P/E/G ratio of 1.38 and a beta of 1.05.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 2nd. Investors of record on Monday, December 3rd will be paid a $0.39 dividend. The ex-dividend date is Friday, November 30th. This represents a $1.56 dividend on an annualized basis and a yield of 1.29%. McKesson’s dividend payout ratio is 12.36%.
In related news, Director N Anthony Coles sold 1,350 shares of McKesson stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $128.69, for a total value of $173,731.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.87% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in MCK. Fort L.P. purchased a new position in McKesson in the 2nd quarter valued at approximately $110,000. Flagship Harbor Advisors LLC purchased a new position in McKesson in the 2nd quarter valued at approximately $118,000. Reilly Financial Advisors LLC grew its stake in McKesson by 506.8% in the 3rd quarter. Reilly Financial Advisors LLC now owns 898 shares of the company’s stock valued at $119,000 after buying an additional 750 shares in the last quarter. Bray Capital Advisors purchased a new position in McKesson in the 3rd quarter valued at approximately $123,000. Finally, FNY Investment Advisers LLC grew its stake in McKesson by 88.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,120 shares of the company’s stock valued at $148,000 after buying an additional 526 shares in the last quarter. Institutional investors and hedge funds own 89.97% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/24/traders-buy-shares-of-mckesson-mck-on-weakness.html.
About McKesson (NYSE:MCK)
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.